Prevalence, risk factors, and treatment outcomes of isoniazid- and rifampicin-mono-resistant pulmonary tuberculosis in Lima, Peru

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Villegas, Leonela ^a   Otero, Larissa ^b   Sterling, Timothy R ^a   Huaman, Moises A ^a   Van Der Stuyft, Patrick ^c,d   Gotuzzo, Eduardo ^b   Seas, Carlos ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; OBSERVATIONAL STUDY; PERU; PREVALENCE; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; SPUTUM CULTURE; SPUTUM SMEAR; TUBERCULOSIS, PULMONARY;

ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; ISONIAZID; MALE; PERU; PREVALENCE; RIFAMPIN; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 84962875885     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152933     Document Type: Article

References (28)

1. Meyssonnier V, Bui T, Veziris N, Jarlier V, Robert J. Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis. BMC Infect Dis. 2014;14(18):1-7.
2. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, et al. Clinical Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis. Clin Infect Dis. 2009;48(2):179-85. doi: 10.1086/595689 PMID: 19086909
3. Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR. Isoniazid-Monoresistant Tuberculosis in the United States, 1993 to 2003. Arch Intern Med. 2008;168(8):1984-92.
4. Organization WH. Anti-tuberculosis drug resistance in the world, Report no. 4 Geneva, Switzerland: World Health Organization Press; 2014.
5. Wang T-Y, Lin S-M, Shie S-S, Chou P-C, Huang C-D, Chung F-T, et al. Clinical Characteristics and Treatment Outcomes of Patients with Low- and High-Concentration Isoniazid-Monoresistant Tuberculosis. PLoS ONE. 2014;9(1). doi: e86316.
6. Mulenga C, Chonde A, Bwalya I, Kapata N, Kakungu-Simpungwe M, Docx S, et al. Low Occurrence of Tuberculosis Drug Resistance among Pulmonary Tuberculosis Patients from an Urban Setting, with a Long-Running DOTS Program in Zambia. Tuberc Res Treat. 2010;2010.
7. Sandgren A, Hollo V, Huitric E, Kodmon C. Complete republication: Epidemiology of tuberculosis in the EU/EEA in 2010-Monitoring the progress towards tuberculosis elimination. Eur J Microbiol Immunol. 2012;2(4):292-6.
8. Espinal M, Kim S, Suarez P, Kam K, Khomenko A, al e. Standard short-course chemotherapy for drugresistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000;283:2537-45. PMID: 10815117
9. Menzies D, Benedetti A, Paydar A, Royce, Pai M, Burman W, et al. Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis. PLoS Med. 2009;6(9):1-14.
10. Timperi R, Han L, Sloutsky A, Becerra M, Nardell E, Salazar J, et al. Drug resistance profiles of Mycobacterium tuberculosis isolates: five years' experience and insight into treatment strategies for MDR-TB in Lima, Peru. Int J Tuberc Lung Dis 2005. 9(2):175-80. PMID: 15732737
11. Jacobson K, Theron D, Victor T, Streicher E, Warren R, Murray M. Treatment outcomes of isoniazidresistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. Aug. 2011;53(4):369-72. doi: 10.1093/cid/cir406 PMID: 21810750
12. Mukinda E, Theron D, Van der Spuy G, Jacobson K, Roscher M, Streicher E, et al. Rise in Rifampicin-Monoresistant Tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis. 2012;16:196-202. doi: 10.5588/ijtld.11.0116 PMID: 22236920
13. Arentz M, Sorensen B, Horne DJ, Walson JL. Systematic Review of the Performance of Rapid Rifampicin Resistance Testing for Drug-Resistant Tuberculosis. PLoS ONE. 2013;8(10):e76533. doi: 10.1371/journal.pone.0076533 PMID: 24098523
14. Balcells M, Thomas S, Godfrey-Faussett P, Grant A. Isoniazid Preventative Therapy and Risk for Resistant Tuberculosis Emerg Infect Dis. 2006;12:744-51.
15. Espinal M, Laserson K, Camacho M, al e. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis. 2001;5:887-93. PMID: 11605880
16. Lo Bue P, Moser K. Isoniazid- and Rifampin-resistant Tuberculosis in San Diego County, California, United States, 1993-2002. Int J Tuberc Lung Dis. 2005;9:501-6. PMID: 15875920
17. Sandman L SN, Davidow A, Bonk S. Risk Factors for Rifampin-monoresistant Tuberculosis. American J of Resp and Critical Care Med 1999;159(2): 468-72. 1999;159(2):468-72.
18. Instituto Nacional de Estadistica e Informatica. Poblacion de Lima Metropolitana 2014. Available from: http://www.inei.gob.pe/media/MenuRecursivo/publicaciones-digitales/Est/Lib1168/libro.pdf.
19. Bonilla AC. Situación de la tuberculosis en el Perú: current status. Acta méd peruana. 2008;25(3):163-7.
20. Ewing J. Detecting Alcoholism: The CAGE Questionnaire. JAMA. 1984;252(14):1905-7. PMID: 6471323
21. Sistema de Focalizacion de Hogares. SISFOH 2015. Available from: http://www.sisfoh.gob.pe/nosotros.shtml?x=1452.
22. Villa-Rosas CL-LR, Oceguera-Palao L. Primary drug resistance in a region with high burden of tuberculosis. A critical problem. Salud Publica Mex. 57:177-79. PMID: 26235779
23. Farley J, Ram M, Pan W, Waldman S, Cassell G, Chaisson R, et al. Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. PLoS Med. 2011;6(7):1-6.
24. al. Be. Predominant Mycobacterium tuberculosis Families and High Rates of Recent Transmission among New Cases Are Not Associated with Primary Multidrug Resistance in Lima, Peru. 2015;53(6):1854-63.
25. Otero L, Krapp F, Tomatis C, Zamudio C, Matthys F, Gotuzzo E, et al. High Prevalence of Primary Multidrug Resistant Tuberculosis in Persons with No Known Risk Factors. PLoS One. 2011;6(10):e26276. doi: 10.1371/journal.pone.0026276 PMID: 22046266
26. Clark C, Li J, Driver C, Munsiff S. Risk Factors for Drug-resistant Tuberculosis Among non-US Born Persons in New York City. Int J Tuberc Lung Dis. 2005;9:964-9. PMID: 16158888
27. Chien JY CY, Wu SG, Lee JJ, Wang JY, Yu CJ. Treatment Outcome of Patients with Isoniazid Monoresistant Tuberculosis. Clin Microbiol Infect. 2015;21(1):59-68. doi: 10.1016/j.cmi.2014.08.008 PMID: 25636929
28. Cox H, Niemann S, Ismailov G, Doshetov D, Orozco J, Blok L, et al. Risk of Acquired Drug Resistance during Short-Course Directly Observed Treatment of Tuberculosis in an Area with High Levels of Drug Resistance. Clin Infect Dis. 2007;44(11):1421-7. PMID: 17479936